RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
Clinical trial NCT07413939 · RECRUITING
Trial details
- NCT number
- NCT07413939
- Sponsor
- Hoffmann-La Roche
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-05-21
- Primary completion
- 2029-05-01
- Enrollment
- 650
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.